Showing 1 - 4 results of 4 for search 'Miguel Fernández Zarzoso', query time: 0.04s Refine Results
  1. 1
    P1609: CAPLACIZUMAB THERAPY IN OLDER PATIENTS (≥60 YEARS) WITH IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP). RESULTS OF THE SPANISH TTP REGISTRY

    P1609: CAPLACIZUMAB THERAPY IN OLDER PATIENTS (≥60 YEARS) WITH IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP). RESULTS OF THE SPANISH TTP REGISTRY by Javier DE LA Rubia, Inés Gómez-Seguí, Joan Cid, David Valcárcel, Rosa Goterris, Miguel Fernández Zarzoso, María Eva Mingot-Castellano, Cristina Pascual Izquierdo, Ana Oliva Hernández, Jorge Martínez Nieto, Laura F. Ávila Idrovo, María Liz Paciello Coronel, Luis M. Hernández

    Published 2023-08-01
    Get full text
    Article
  2. 2
    S305: PHASE 2 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER STUDY OF RECOMBINANT ADAMTS13 IN PATIENTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA

    S305: PHASE 2 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER STUDY OF RECOMBINANT ADAMTS13 IN PATIENTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA by Marie Scully, Jovanna Baptista, Indranil Bhattacharya, Spero Cataland, Paul Coppo, Loredana Cuccia, Tina Dutt, Shih-Han Susan Huang, Cristina Pascual Izquierdo, María Eva Mingot-Castellano, Aric Parnes, Katerina Pavenski, Kavitha Rajavel, Isidro Jarque, Linda T. Wang, Miguel Fernández Zarzoso, Andy Zhu, Björn Mellgård

    Published 2023-08-01
    Get full text
    Article
  3. 3
    Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).

    Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM). by Julia González-Rincón, José A Garcia-Vela, Sagrario Gómez, Belén Fernández-Cuevas, Sara Nova-Gurumeta, Nuria Pérez-Sanz, Miguel Alcoceba, Marcos González, Eduardo Anguita, Javier López-Jiménez, Eva González-Barca, Lucrecia Yáñez, Ernesto Pérez-Persona, Javier de la Serna, Miguel Fernández-Zarzoso, Guillermo Deben, Francisco J Peñalver, María C Fernández, Jaime Pérez de Oteyza, M Ángeles Andreu, M Ángeles Ruíz-Guinaldo, Raquel Paz-Arias, M Dolores García-Malo, Valle Recasens, Rosa Collado, Raúl Córdoba, Belén Navarro-Matilla, Margarita Sánchez-Beato, José A García-Marco

    Published 2021-01-01
    Get full text
    Article
  4. 4
    High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance

    High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and... by José A. García-Marco, Javier López Jiménez, Valle Recasens, Miguel Fernández Zarzoso, Eva González-Barca, Nieves Somolinos De Marcos, M. Jose Ramírez, Francisco Javier Peñalver Parraga, Lucrecia Yañez, Javier De La Serna Torroba, Maria Dolores Garcia Malo, Guillermo Deben Ariznavarreta, Ernesto Perez Persona, M. Angeles Ruiz Guinaldo, Raquel De Paz Arias, Elena Bañas Llanos, Isidro Jarque, M. del Carmen Fernandez Valle, Ana Carral Tatay, Jaime Perez De Oteyza, Eva Maria Donato Martin, Inmaculada Perez Fernández, Rafael Martinez Martinez, M. Angeles Andreu Costa, Diana Champ, Julio García Suarez, Marcos González Díaz, Secundino Ferrer, Félix Carbonell, José A. García-Vela

    Published 2019-11-01
    Get full text
    Article

Search Tools: